PARP in vivo Pharmacodynamic Assay
Quantitative PAR ELISA
AMSBIO now offers a new second generation PARP in vivo
Pharmacodynamic Assay that accurately measures net PAR levels in cellular extracts and has been used to document differences in PAR levels in human tumor lysates from a variety of tissues, organs and xenografts.
This assay provides a valuable tool for research and clinical trials of PARP inhibitors as anti-cancer drugs.
||Only PAR ELISA assay available
||Compatible with laboratory automation
||Only assay validated to USP recommendations
- Quantitation of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
- Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
- Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
- Facilitating development of PARP and PARG targeted therapeutics.
Poly-ADP-ribose polymerase (PARP) is a protein involved in a number of cellular processes including catalysing the NAD-dependent addition of PAR onto itself and other
adjacent nuclear proteins. PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia and neurodegeneration.
The discovery that breast cancers deficient in homologous recombination are sensitive to non-toxic PARP inhibitors resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.
In December 2014, AstraZeneca‘s ovarian cancer drug Lynparza™ (olaparib) became the first PARP inhibitor to be granted approval by the European Commission and the US Food and Drug Administration (FDA).
The The PARP in vivo Pharmacodynamic Assay uses a validated sample processing regime and a chemiluminescent, sandwich ELISA format, with pre-coated 96-stripwell plates. The Assay
reports PAR level with high signal to noise ratio; sensitivity of 2 pg/ml and a linear dynamic range to 1000 pg/ml. Consequently the PARP in vivo Pharmacodynamic Assay offers an exciting new tool that provides
evidence of drug action on molecular targets and generates baseline values that may be used to stratify patient response to therapy.
Further information on the complete range of PARP assay kits, enzymes and antibodies visit our PARP page.